title: Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders.
abstract: Childhood neurotransmitter disorders are increasingly recognised as an expanding group of inherited neurometabolic syndromes. They are caused by disturbance in synthesis, metabolism, and homeostasis of the monoamine neurotransmitters, including the catecholamines (dopamine, norepinephrine, and epinephrine) and serotonin. Disturbances in monoamine neurotransmission will lead to neurological symptoms that often overlap with clinical features of other childhood neurological disorders (such as hypoxic ischaemic encephalopathy, cerebral palsy, other movement disorders, and paroxysmal conditions); consequently, neurotransmitter disorders are frequently misdiagnosed. The diagnosis of neurotransmitter disorders is made through detailed clinical assessment, analysis of cerebrospinal fluid neurotransmitters, and further supportive diagnostic investigations. Early and accurate diagnosis of neurotransmitter disorders is important, as many are amenable to therapeutic intervention. The principles of treatment for monoamine neurotransmitter disorders are mainly directly derived from understanding these metabolic pathways. In disorders characterized by enzyme deficiency, we aim to increase monoamine substrate availability, boost enzyme co-factor levels, reduce monoamine breakdown, and replace depleted levels of monoamines with pharmacological analogs as clinically indicated. Most monoamine neurotransmitter disorders lead to reduced levels of central dopamine and/or serotonin. Complete amelioration of motor symptoms is achievable in some disorders, such as Segawa's syndrome, and, in other conditions, significant improvement in quality of life can be attained with pharmacotherapy. In this review, we provide an overview of the clinical features and current treatment strategies for childhood monoamine neurotransmitter disorders.
authors.affiliation: Molecular Neurosciences, Developmental Neurosciences Programme, Institute of Child Health, University College London, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Ng
authors.forename: S J R
authors.initials: SJ
authors.lastname: Heales
authors.forename: M A
authors.initials: MA
authors.lastname: Kurian
mesh_terms: D002395:Catecholamines / Q000378:metabolism*; D002648:Child; D004298:Dopamine / Q000378:metabolism; D005492:Folic Acid / Q000502:physiology; D006801:Humans; D009422:Nervous System Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010661:Phenylketonurias / Q000188:drug therapy; D012701:Serotonin / Q000378:metabolism*
chemical_list: D002395:Catecholamines; D018377:Neurotransmitter Agents; D012701:Serotonin; D005492:Folic Acid; D004298:Dopamine